| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5739135 | AMRYT | Inhibitors of microsomal triglyceride transfer protein and method |
Apr, 2015
(9 years ago) | |
| US5712279 | AMRYT | Inhibitors of microsomal triglyceride transfer protein and method |
Feb, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6492365 | AMRYT | Microsomal triglyceride transfer protein |
Dec, 2019
(4 years ago) | |
| US10555938 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(10 months from now) | |
| US9433617 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(10 months from now) | |
| US8618135 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(10 months from now) | |
| US10016404 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(10 months from now) | |
| US9364470 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(10 months from now) | |
| US9265758 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(10 months from now) | |
| US9861622 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(10 months from now) | |
| US7932268 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Aug, 2027
(3 years from now) | |
Juxtapid is owned by Amryt.
Juxtapid contains Lomitapide Mesylate.
Juxtapid has a total of 11 drug patents out of which 3 drug patents have expired.
Expired drug patents of Juxtapid are:
- US6492365
- US5739135
- US5712279
Juxtapid was authorised for market use on 21 December, 2012.
Juxtapid is available in capsule;oral dosage forms.
Juxtapid can be used as treatment of hypercholesterolemia by decreasing the amount or activity of microsomal triglyceride transfer protein in patients with homozygous familial hypercholesterolemia, a dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses, treatment of hypercholesterolemia, hyperlipidemia and hyperlipoproteinemia in patients with homozygous familial hypercholesterolemia, a dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses.
Drug patent challenges can be filed against Juxtapid from 21 December, 2016.
The generics of Juxtapid are possible to be released after 19 August, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2017 |
| Orphan Drug Exclusivity(ODE-36) | Dec 21, 2019 |
Drugs and Companies using LOMITAPIDE MESYLATE ingredient
NCE-1 date: 21 December, 2016
Market Authorisation Date: 21 December, 2012
Treatment: Treatment of hypercholesterolemia by decreasing the amount or activity of microsomal triglyceride transfer protein in patients with homozygous familial hypercholesterolemia; A dosing regimen for the t...
Dosage: CAPSULE;ORAL
JUXTAPID family patents
